What are alternative therapies to Trulicity (dulaglutide) for an adult with type 2 diabetes?

Alternative Therapies to Trulicity (Dulaglutide)

Add either an SGLT2 inhibitor or another GLP-1 receptor agonist (such as semaglutide or liraglutide) to metformin and lifestyle modifications as the preferred alternative to Trulicity for type 2 diabetes management. 1

Primary Alternatives Based on Clinical Context

The choice of alternative depends critically on your patient's comorbidities:

For Patients with Heart Failure (HFrEF or HFpEF)

• Use an SGLT2 inhibitor (empagliflozin, dapagliflozin, canagliflozin) as the preferred alternative
• This recommendation applies regardless of current A1C level 2
• SGLT2 inhibitors reduce all-cause mortality, major adverse cardiovascular events, and hospitalizations for heart failure 1

For Patients with Chronic Kidney Disease (eGFR 20-60 mL/min/1.73 m² or albuminuria)

• Either an SGLT2 inhibitor OR another GLP-1 RA (semaglutide, liraglutide) is appropriate 2
• Both classes slow CKD progression and reduce cardiovascular events
• Note: SGLT2 inhibitor glycemic benefits diminish at eGFR <45 mL/min/1.73 m² 2

For Patients with Advanced CKD (eGFR <30 mL/min/1.73 m²)

• Prefer another GLP-1 RA (semaglutide or liraglutide) over SGLT2 inhibitors 2
• Lower hypoglycemia risk and continued cardiovascular benefit in this population

For Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Obesity

• Consider semaglutide or tirzepatide (dual GIP/GLP-1 agonist) 2
• These agents show potential benefits for MASH and provide superior weight loss
• Tirzepatide demonstrated greater weight loss than semaglutide (-3.78 kg difference) 3

Alternative GLP-1 Receptor Agonists

If switching within the GLP-1 RA class:

Semaglutide (subcutaneous or oral):

• Demonstrated superior glycemic control compared to dulaglutide (HbA1c reduction difference of -0.27%) 4
• Greater weight loss than dulaglutide (-2.85 kg difference) 3
• Reduces all-cause mortality, major adverse cardiovascular events, and stroke 1

Liraglutide (daily injection):

• Comparable cardiovascular and kidney outcomes to dulaglutide 5
• May have lower all-cause mortality compared to dulaglutide in some analyses 5
• Reduces all-cause mortality, major adverse cardiovascular events, and stroke 1

Tirzepatide (dual GIP/GLP-1 agonist):

• Superior weight loss compared to all single GLP-1 RAs (mean 9.7 kg reduction) 3
• Consider for patients requiring maximal weight reduction

What NOT to Use

Avoid DPP-4 inhibitors (sitagliptin, linagliptin, saxagliptin) as alternatives to Trulicity—they do not reduce morbidity or all-cause mortality and represent inferior therapy 1

Important Caveats

• All GLP-1 RAs carry similar gastrointestinal adverse effects (nausea, vomiting, diarrhea), typically transient and mild-to-moderate 3, 5
• SGLT2 inhibitors increase DKA risk, particularly in type 1 diabetes (not relevant here) but remain safe in type 2 diabetes 2
• Dulaglutide demonstrated cardiovascular benefits in the REWIND trial, so switching should be based on specific clinical indications, not arbitrary preference 6
• The thyroid C-cell tumor risk observed in rodent studies with dulaglutide has unknown human relevance 7

Practical Algorithm

1. Identify dominant comorbidity: Heart failure → SGLT2 inhibitor; CKD with eGFR >30 → SGLT2 inhibitor or GLP-1 RA; CKD with eGFR <30 → GLP-1 RA; MASLD/obesity → semaglutide or tirzepatide
2. If no specific comorbidity: Choose between SGLT2 inhibitor or alternative GLP-1 RA based on patient preference for injection frequency and cost considerations
3. Within GLP-1 RA class: Semaglutide offers slightly better glycemic control and weight loss than dulaglutide; tirzepatide offers maximal weight loss